Band Therapeutics

BT200 is a PEGylated aptamer that binds A1 domain of human VWF.

• BT200 has a cognate aptamer reversal agent (BT101) with in vivo proof of mechanism in non-human primates.

Selected Publications:

• Basic pharmacology of BT200 and BT101 (Zhu et al 2020a and 2020b)
• https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14755
• https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14822

• Pharmacology of VWF related to bleeding disorders with 1st gen aptamer (Jilma-Stohlawetz 2012)
• https://pubmed.ncbi.nlm.nih.gov/22740102/

BT200 Phase 1 program (NCT04103034) was completed in 4Q20.

• 112 healthy volunteers in SAD, MAD, relative bioavailability, and pharmacologic challenge studies.
• Overall safety & tolerability profile is excellent.
• PK profile compatible with once weekly, small volume subcutaneous dosing regimen.
• Headline Clinical Proof of Mechanism results presented at European Hematology Association Congress 2021.
• BT200 Phase 1 clinical proof of mechanism oral presentation at European Hematology Association Virtual Congress, June 9 - 17, 2021
  Title: "HALF-LIFE PROLONGATION OF VON WILLEBRAND FACTOR: A NEW THERAPEUTIC STRATEGY FOR HAEMOPHILIA A AND VON WILLEBRAND DISEASE"
  Session Title: Dilemmas in coagulation and thrombosis
  Final Abstract Code: S302
  Narrated slide presentation video link

BT200 Phase 2 pilot study in hereditary bleeding disorders (NCT04677803) initiated in 1Q21.

• “Basket design” trial includes patients with either Von Willebrand Disease or Hemophilia A.
• Headline clinical proof of concept results presented at ISTH meeting in July 2021.
• BT200 Phase 2 clinical proof of concept in Von Willebrand Disease Type 2b oral presentation at International Society for Thrombosis and Haemostasis Virtual Congress, July 17-21, 2021
  Title: BT200 increases von Willebrand factor (VWF), FVIII and platelet counts in patients with von Willebrand disease (VWD) type IIb
  Abstract Number: OC 72.1
  Session Date: 2021-07-21
  Session Time: 13:00 - 14:00 U.S. Eastern Daylight Time
• BT200 Phase 2 clinical proof of concept in hemophilia A late-breaking clinical trial presentation at International Society for Thrombosis and Haemostasis Virtual Congress, July 17-21, 2021
  Abstract Title: The VWF-A1 domain binding aptamer BT200 prolongs the half-lives of different factor VIII (FVIII) products in patients with severe hemophilia A and increases FVIII levels in non-severe hemophilia A.
  Abstract Presentation Number: LB 02.1
  Session Title: Late-breaking Abstract Session II
  Session Date: Wednesday, July 21, 2021
  Session Time: 10:00:00 AM - 11:00:00 AM U.S. Eastern Daylight Time